

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3387644

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
FLAMEL TECHNOLOGIES		12/16/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	FLAMEL IRELAND LIMITED	
<b>Street Address:</b>	ARTHUR COX BUILDING	
<b>Internal Address:</b>	EARLSFORT TERRACE	
<b>City:</b>	DUBLIN	
<b>State/Country:</b>	IRELAND	
<b>Postal Code:</b>	2	
<b>PROPERTY NUMBERS Total: 18</b>		
<b>Property Type</b>	<b>Number</b>	
Patent Number:	7879362	
Patent Number:	8101209	
Patent Number:	8507003	
Patent Number:	7683024	
Patent Number:	8652523	
Patent Number:	8821935	
Patent Number:	7906145	
Patent Number:	8084045	
Patent Number:	8734850	
Patent Number:	8895063	
Patent Number:	8652529	
Patent Number:	8445023	
Application Number:	11707054	
Application Number:	12641773	
Application Number:	12790201	
Application Number:	12905387	
Application Number:	13014137	
Application Number:	14081038	

**CORRESPONDENCE DATA****Fax Number:** (202)517-6322

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2025171888**Email:** badonovan@pbnlaw.com**Correspondent Name:** PORZIO, BROMBERG & NEWMAN P.C.**Address Line 1:** 1200 NEW HAMPSHIRE AVE., NW**Address Line 2:** SUITE 710**Address Line 4:** WASHINGTON, D.C. 20036

<b>ATTORNEY DOCKET NUMBER:</b>	022290
<b>NAME OF SUBMITTER:</b>	MATTHEW J. LASKOSKI
<b>SIGNATURE:</b>	/Matthew J. Laskoski/
<b>DATE SIGNED:</b>	06/08/2015

**Total Attachments: 3**

source=FlamelTechnologiesAssignment#page1.tif

source=FlamelTechnologiesAssignment#page2.tif

source=FlamelTechnologiesAssignment#page3.tif

## CONFIRMATORY ASSIGNMENT


This Confirmatory Assignment is made and entered into effective December 16, 2014 by and between Flamel Technologies, a corporation organized under the laws of France, located at 33 Avenue Dr. Georges Lévy, Vénissieux 69200, France hereinafter referred to as "Assignor", and Flamel Ireland Limited, a corporation organized under the laws of Ireland with registration number 542077, located at Arthur Cox building, Earlsfort Terrace, Dublin 2, Ireland hereinafter referred to as "Assignee".

WHEREAS, pursuant to the Patent Assignment Agreement between Assignor and Assignee dated December 16, 2014 ("Patent Assignment Agreement") the Assignor agreed to assign all of its right, title and interest in and to its patent(s) and/or patent application(s) listed on the attached Exhibit A ("the Patents") effective December 16, 2014.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by this Confirmatory Assignment confirms having assigned, transferred, conveyed, and delivered to Assignee, its successors and assigns, all right, title and interest of the Assignor in and to the Patents. The right, title and interest is to be held and enjoyed by Assignee, its successors and assigns, as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.


IN WITNESS WHEREOF, the undersigned has caused this Confirmatory Assignment to be duly executed and delivered on this 16<sup>th</sup> day of December, 2014.

FLAMEL TECHNOLOGIES (Assignor)

By: 

Date: 12/16/14

FLAMEL IRELAND LIMITED (Assignee)

By: 

Date: 12/16/14

## **EXHIBIT A**

<b>Application No./ Patent No.</b>	<b>Filing Date/ Issue Date</b>	<b>Title</b>
11/723,553  7,879,362	March 21, 2007  February 1, 2011	Oral pharmaceutical composition with controlled release and prolonged absorption
10/826,690  8,101,209	April 19, 2004  January 24, 2012	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/507,886  8,507,003	March 14, 2003  August 13, 2013	Compressed tablets comprising microcapsules with modified release
10/516,733  7,683,024	June 3, 2003  March 23, 2010	Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications
10/522,252  8,652,523	July 28, 2003  February 18, 2014	Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility
11/583,940  8,821,935	October 20, 2006  September 2, 2014	Microcapsules with modified release of active principles with low solubility for oral delivery
10/510,643  7,906,145	April 7, 2003  March 15, 2011	Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for modified release of active principle(s)
13/014,137	January 26, 2011	Oral pharmaceutical formulation in the form of an aqueous suspension of microcapsules for modified release of active principle(s)
10/580,023  8,084,045	November 19, 2004  December 27, 2011	Pharmaceutical formulations for the prolonged release of active principle(s) and their applications
10/996,780  8,734,850	November 24, 2004  May 27, 2014	Oral medicinal product with modified release of at least one active principle, in multimicrocapsular form
11/651,577  8,895,063	January 10, 2007  November 25, 2014	Oral dosage form comprising an antimisuse system

<b>Application No./ Patent No.</b>	<b>Filing Date/ Issue Date</b>	<b>Title</b>
11/439,432	May 24, 2006	Anti-misuse microparticulate oral pharmaceutical form
8,652,529	February 18, 2014	
12/638,739	December 15, 2009	Anti-misuse microparticulate oral pharmaceutical form
8,445,023	May 21, 2013	
14/081,038	November 15, 2013	Anti-misuse microparticulate oral pharmaceutical form
11/707,054	February 16, 2007	Microparticulate pharmaceutical forms resistant to immediate release of the active principle in the presence of alcohol
12/790,201	May 28, 2010	Controlled-release floating pharmaceutical compositions
12/641,773	December 18, 2009	Composition comprising an active agent with low aqueous solubility
12/905,387	October 15, 2010	Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile